title: Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis.
abstract: Apoptotic capacity (AC) in primary lymphocytes may be a marker for cancer susceptibility, and functional single nucleotide polymorphisms (SNPs) in genes involved in apoptotic pathways may modulate cellular AC in response to DNA damage. To further examine the correlation between apoptotic genotypes and phenotype, we genotyped 14 published SNPs in 11 apoptosis-related genes (i.e., p53, Bcl-2, BAX, CASP9, DR4, Fas, FasL, CASP8, CASP10, CASP3, and CASP7) and assessed the AC in response to benzo[a]pyrene-7,8-9,10-diol epoxide (BPDE) in cultured primary lymphocytes from 172 cancer-free subjects. We found that among these 14 SNPs, R72P, intron 3 16-bp del/ins, and intron 6 G>A in p53, -938C>A in Bcl-2, and I522L in CASP10 were significant predictors of the BPDE-induced lymphocytic AC in single-locus analysis. In the combined analysis of the three p53 variants, we found that the individuals with the diplotypes carrying 0-1 copy of the common p53 R-del-G haplotype had higher AC values compared to other genotypes. Although the study size may not have the statistical power to detect the role of other SNPs in AC, our findings suggest that some SNPs in genes involved in the intrinsic apoptotic pathway may modulate lymphocytic AC in response to BPDE exposure in the general population. Larger studies are needed to validate these findings for further studying individual susceptibility to cancer and other apoptosis-related diseases.
authors.affiliation: Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Zhibin
authors.initials: Z
authors.lastname: Hu
authors.forename: Chunying
authors.initials: C
authors.lastname: Li
authors.forename: Kexin
authors.initials: K
authors.lastname: Chen
authors.forename: Li-E
authors.initials: LE
authors.lastname: Wang
authors.forename: Erich M
authors.initials: EM
authors.lastname: Sturgis
authors.forename: Margaret R
authors.initials: MR
authors.lastname: Spitz
authors.forename: Qingyi
authors.initials: Q
authors.lastname: Wei
references.citation: Nat Genet. 2003 Mar;33(3):357-65
references.pmid: 12567188
references.citation: Toxicol Appl Pharmacol. 1998 Aug;151(2):367-76
references.pmid: 9707513
references.citation: Prostate Cancer Prostatic Dis. 2006;9(3):284-92
references.pmid: 16733517
references.citation: Mol Immunol. 1997 Jun;34(8-9):577-82
references.pmid: 9393960
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1169-77
references.pmid: 17637392
references.citation: J Natl Cancer Inst. 2004 Dec 15;96(24):1866-9
references.pmid: 15601643
references.citation: Science. 1998 Oct 9;282(5387):290-3
references.pmid: 9765154
references.citation: CA Cancer J Clin. 2005 May-Jun;55(3):178-94
references.pmid: 15890640
references.citation: Science. 1995 Mar 10;267(5203):1456-62
references.pmid: 7878464
references.citation: Bioinformatics. 2001 Sep;17(9):838-9
references.pmid: 11590100
references.citation: Hum Mutat. 2006 Mar;27(3):242-8
references.pmid: 16419081
references.citation: J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72
references.pmid: 11058619
references.citation: Am J Hum Genet. 2003 Nov;73(5):1162-9
references.pmid: 14574645
references.citation: Semin Hematol. 1997 Oct;34(4 Suppl 5):9-19
references.pmid: 9408956
references.citation: Nature. 1983 Jun 9-15;303(5917):468-72
references.pmid: 6304528
references.citation: Cancer Lett. 2002 Sep 26;183(2):123-30
references.pmid: 12065086
references.citation: Cancer Res. 1998 Apr 15;58(8):1593-8
references.pmid: 9563466
references.citation: Hum Pathol. 1996 Feb;27(2):102-10
references.pmid: 8617450
references.citation: Carcinogenesis. 1995 Sep;16(9):2117-24
references.pmid: 7554063
references.citation: Nature. 2004 Nov 18;432(7015):307-15
references.pmid: 15549092
references.citation: Cancer Lett. 2002 Dec 10;187(1-2):199-205
references.pmid: 12359369
references.citation: Mol Cell Biol. 1999 Feb;19(2):1092-100
references.pmid: 9891044
references.citation: J Immunol. 2003 Jan 1;170(1):132-8
references.pmid: 12496392
references.citation: Cancer Res. 1985 Jan;45(1):51-6
references.pmid: 3155495
references.citation: Hum Immunol. 2003 Feb;64(2):285-9
references.pmid: 12559631
references.citation: Toxicology. 2004 Jun 1;199(1):35-46
references.pmid: 15125997
references.citation: Cancer Res. 2003 Mar 15;63(6):1157-9
references.pmid: 12649168
references.citation: Trends Genet. 1995 Mar;11(3):101-5
references.pmid: 7732571
references.citation: Cancer Res. 1998 May 15;58(10):2102-6
references.pmid: 9605752
references.citation: J Pathol. 1996 May;179(1):10-4
references.pmid: 8691332
references.citation: J Cell Biol. 1994 Jan;124(1-2):1-6
references.pmid: 8294493
references.citation: J Rheumatol. 2002 Jun;29(6):1183-8
references.pmid: 12064832
references.citation: J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6
references.pmid: 15240787
references.citation: Physiol Rev. 1980 Oct;60(4):1107-66
references.pmid: 7001511
references.citation: Carcinogenesis. 2000 Mar;21(3):485-95
references.pmid: 10688869
references.citation: J Hum Genet. 2004;49(8):449-454
references.pmid: 15278764
references.citation: Science. 2004 Jul 30;305(5684):626-9
references.pmid: 15286356
references.citation: Science. 1998 Aug 28;281(5381):1305-8
references.pmid: 9721089
references.citation: Genes Immun. 2001 Apr;2(2):117-8
references.pmid: 11393657
references.citation: Nature. 2001 May 17;411(6835):342-8
references.pmid: 11357141
references.citation: Cell. 1995 Jan 27;80(2):293-9
references.pmid: 7834749
references.citation: Clin Cancer Res. 2001 Jun;7(6):1688-97
references.pmid: 11410508
references.citation: Lung Cancer. 2003 Oct;42(1):1-8
references.pmid: 14512182
references.citation: J Natl Cancer Inst. 2002 May 1;94(9):681-90
references.pmid: 11983757